ArticleFrontiers in medicine2026
Association between platelet levels and bleeding events in patients with acute-on-chronic liver failure treated with an artificial liver support system.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platelet reduction is associated with an increased risk of bleeding in patients with chronic liver disease. However, the association between platelet levels and bleeding events in patients with liver failure treated with an artificial liver support system (ALSS) remains unclear. Methods: This retrospective study included patients with acute-on-chronic liver failure (ACLF) who received ALSS treatment. Logistic and linear regression analyses were employed to assess the association between platelet levels and bleeding events during hospitalization and the relationship between sessions of ALSS treatment and platelet reduction rates. Results: We included 262 patients, of whom 56 (21.4%) experienced bleeding events during hospitalization. Baseline platelet levels in patients with bleeding events were significantly lower than those in patients without bleeding events (59.0 (39.0 ~ 89.3) × 10 Conclusion: Patients with ACLF who underwent ALSS treatment with lower baseline platelet levels were at an increased risk of bleeding during hospitalization, whereas the platelet reduction rate was not independently associated with bleeding risk. These findings underscore the importance of baseline platelet count rather than platelet reduction for early risk stratification in patients with ACLF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.